First clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 Meeting Abstract
| Authors: | Yap, T. A.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Moreno Garcia, V.; Punekar, S. R.; Calvo, E.; Sonpavde, G. P.; Awad, M.; Riess, J. W.; Hernández-Guerrero, T.; Herzberg, B.; Italiano, A.; Swalduz, A.; LoRusso, P.; Smit, E. F.; Garon, E. B.; Novotny, W.; Guo, R. |
| Abstract Title: | First clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 |
| Meeting Title: | 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 211 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Oct 23-25 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-10-01 |
| Start Page: | S1 |
| End Page: | S2 |
| Language: | English |
| ACCESSION: | WOS:001345547300002 |
| DOI: | 10.1016/j.ejca.2024.114530 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1 Oral -- Article number: 114530 -- Source: Wos |
